Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GeRX-461
- Development stage
- Preclinical
- Lead developer
- Gelteq
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral
01
Overview
GeRX-461 is an oral gel delivery formulation of a diabetes medication developed by Gelteq. It utilizes Gelteq's proprietary ingestible gel-based delivery platform, which is designed to improve drug absorption, solubility, and precise dosing, particularly for patients with dysphagia (difficulty swallowing) or compliance challenges. The formulation is currently in preclinical development for the treatment of diabetes.
Beyond the preview
Go deeper on GeRX-461.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeRX-461.